Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Codiak Biosciences
About
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $61M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 29, 2017 | Series C | $76.50M | 1 | — | — | Detail |
| Jan 26, 2016 | Series B | $61M | 1 |
ARCH Venture Partners
|
— | Detail |
| Nov 17, 2015 | Series A | $31M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Series C |
